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Abstract
The successive events that cells experience throughout development shape their intrinsic
capacity to respond and integrate RTK inputs. Cellular responses to RTKs rely on different
mechanisms of regulation that establish proper levels of RTK activation, define duration of
RTK action, and exert quantitative/qualitative signalling outcomes. The extent to which cells
are competent to deal with fluctuations in RTK signalling is incompletely understood. Here,
we employ a genetic system to enhance RTK signalling in a tissue-specific manner. The
chosen RTK is the hepatocyte growth factor (HGF) receptor Met, an appropriate model due
to its pleiotropic requirement in distinct developmental events. Ubiquitously enhanced Met
in Cre/loxP-based Rosa26stopMet knock-in context (Del-R26Met) reveals that most tissues
are capable of buffering enhanced Met-RTK signalling thus avoiding perturbation of devel-
opmental programs. Nevertheless, this ubiquitous increase of Met does compromise
selected programs such as myoblast migration. Using cell-type specific Cre drivers, we
genetically showed that altered myoblast migration results from ectopic Met expression in
limb mesenchyme rather than in migrating myoblasts themselves. qRT-PCR analyses
show that ectopic Met in limbs causes molecular changes such as downregulation in
the expression levels of Notum and Syndecan4, two known regulators of morphogen gradi-
ents. Molecular and functional studies revealed that ectopic Met expression in limb mesen-
chyme does not alter HGF expression patterns and levels, but impairs HGF bioavailability.
Together, our findings show that myoblasts, in which Met is endogenously expressed, are
capable of buffering increased RTK levels, and identify mesenchymal cells as a cell type
vulnerable to ectopic Met-RTK signalling. These results illustrate that embryonic cells are
sensitive to alterations in the spatial distribution of RTK action, yet resilient to fluctuations in
signalling levels of an RTK when occurring in its endogenous domain of activity.
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Author Summary
The need to achieve precise control of RTK activation is highlighted by human pathologies
such as congenital malformations and cancers caused by aberrant RTK signalling. Identi-
fying strategies to restrain RTK activity in cancer and/or to reactivate RTKs for counteract-
ing degenerative processes is the focus of intense research efforts. We designed a genetic
system to enhance RTK signalling during mouse embryogenesis in order to examine the
competence of cells to deal with changes in RTK inputs. Our data reveal that most embry-
onic cells are capable of: 1) handling moderate perturbations in Met-RTK expression lev-
els, 2) imposing a threshold of intracellular signalling activation despite elevated Met-RTK
inputs, and/or 3) integrating variable quantitative levels of Met-RTK signalling within bio-
logical responses. Our results also establish that certain cell types, such as limb mesen-
chyme, are particularly vulnerable to alterations of the spatial distribution of RTK
expression. The vulnerability of limb mesenchyme to enhanced Met levels is illustrated by
gene expression changes, by interference with HGF chemoattractant effects, and by loss of
accessibility to incoming myoblasts, leading to limb muscle defects. These findings high-
light how resilience versus vulnerability to RTK fluctuation is strictly linked to cell compe-
tence and to the robustness of the developmental programs they undergo.
Introduction
Signalling by receptor tyrosine kinases (RTKs) coordinates developmental processes and
ensures tissue homeostasis. Upon ligand stimulation, RTKs activate a number of intracellular
signalling cascades to influence in cells identity acquisition, movement, survival, and prolifera-
tion [1]. Cellular responses to RTKs rely on different mechanisms of regulation that establish
proper levels of RTK activation, define timing of action, and exert quantitative and/or qualita-
tive signalling outcomes. Mechanisms of RTK regulation involve transcriptional or post-tran-
scriptional control, lateral membrane distribution, endocytosis, and intracellular
compartmentalisation, for example early endosomes in which RTKs activate distinct effectors
[2, 3]. The need to achieve precise control of RTK activation is highlighted by human patholo-
gies caused by altered RTK signalling such as congenital malformations and cancer [2], and
establishing strategies to restrain RTK function in disease cells is currently the focus of intense
efforts [4]. Despite extensive studies, we are still far from understanding the fundamental prin-
ciples of how cells perceive and integrate both quantitative and qualitative RTK signalling levels
and how excess RTK signalling can perturb cellular and developmental homeostasis.
The vulnerability of cells to excess RTK signalling is conditioned by their competence to
respond to an instructive RTK ligand by changing their behaviour. Such competence is influ-
enced by the previous history of cells, during which their intrinsic capacity to respond to a
given signal has been shaped through gene regulatory events leading to the acquisition or loss
of molecular components necessary for the response (e.g. receptors, co-receptors, signalling
modules, and transcription factors). Cellular responses to a given RTK are also conditioned by
the simultaneous activation of other signalling inputs and by their synergistic or antagonistic
nature [5, 6]. Vulnerability of cells to an excess of a given RTK may also vary according to
whether such excess results in an enhanced activation over endogenous levels, or whether this
excess would result in ectopic activation in cells that would not normally express the RTK.
Thus, cell vulnerability is most likely determined by the relative contribution of all these aspects
and by the intensity of RTK signalling fluctuation.
Developmental Vulnerability to Enhanced RTK
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As highlighted by studies in cellular and animal models, constitutive activation of RTKs
results in altered duration/intensity of intracellular signalling and/or participation of additional
pathways not recruited under physiological conditions. Unsurprisingly, molecular pathways
activated by aberrant RTKs are integrated within other signalling networks through crosstalk,
causing signalling perturbations that in turn impact cell behaviour [7]. However, most of these
studies have involved models in which enhanced activation of RTKs is achieved through strate-
gies such as activating point mutations, oncogenic translocation, and gene amplification. These
strategies lead to constitutive activated forms of RTKs that escape regulatory mechanisms,
which normally modulate signalling intensity and duration. These strategies are therefore inap-
propriate to assess whether cells are capable of: a) buffering subtle fluctuations in RTK activa-
tion over physiological levels, and b) imposing a threshold of intracellular signalling activation
despites the level of RTK input.
In order to provide insights into the capacity of cells to integrate enhanced RTK signalling
above endogenous levels within developmental programs, we have engineered the first mouse
model in which RTK signalling can be conditionally enhanced in a tissue-specific manner.
Importantly, we opted for the wild-type version of the RTK to avoid perturbation of cellular
mechanisms regulating signalling maintenance, extinction, and intracellular location. The cho-
sen RTK is the hepatocyte growth factor (HGF) receptor Met, an appropriate model due to: a)
its pleiotropic properties elicited in distinct cell types [8]; b) the variety of biological response
regulated in different developmental programs and tissue homeostasis [9–11]; c) its impact on
tumour evolution and resistance to anticancer therapies [8, 12–14]. During embryogenesis,
alteration of the HGF/Met system in mice causes liver, placenta, muscle, and neuronal defects
[15–23]. Development of muscle in the limb represents a biological model of crosstalk between
limb mesenchyme and myoblasts that migrate from the somites to colonize the limb buds.
Whereas migrating myoblasts express Met, limb mesenchymal cells produce the HGF acting as
a chemoattractant for incoming myoblasts [15, 18, 23]. Acquisition of motility by myoblast at
limb levels is strictly dependent on HGF/Met, with no other redundant molecules capable of
bypassing loss of Met signalling.
To achieve conditional gain of wild-type Met-RTK signalling above an endogenous level, we
employed the Cre-loxP strategy [24]. In particular, we generated Rosa26LacZ-stop-Met (R26stopMet)
transgenic mice that permit, upon Cre-mediated excision, to: 1) increase Met expression above
endogenous levels and/or 2) impose Met signalling in cells that do not normally express Met
[24]. By using the R26stopMet transgenic mice, we previously demonstrated that enhancing Met
signalling in the neural lineage delays the onset of motor neuron degeneration in a murine
model of amyotrophic lateral sclerosis [24]. Moreover, these mice revealed the levels of HGF
required for retinal ganglion cells survival and axonal growth after optic nerve axotomy lesion
[25]. In the present study, we combined R26stopMet transgenic mice with either ubiquitous or
tissue-specific-Cre transgenic lines to determine which cells are vulnerable to moderately
enhanced Met-RTK expression levels during development. These genetic studies revealed that
exogenous Met phosphorylation is restricted to few territories in developing embryos, thus
highlighting the existence of a map of competence to Met activation. Intriguingly, we found
that most cells, whether relying on endogenous Met signalling or being normally devoid of Met
expression, can buffer a moderate increase in RTK signalling. This correlates with a limited
propagation of the enhanced Met-RTK input to its downstream signals. This demonstrates
that the signalling network is resilient to intensity changes in Met-RTK input for normal devel-
opment. However, one cell type, limb mesenchyme, is vulnerable to ectopic Met expression, as
evidenced by a drastic impairment of muscle morphogenesis, and by molecular changes in the
expression levels of some extracellular regulators of morphogens. Ectopic expression of Met in
mesenchymal cells, although not interfering with early limb patterning events, prevents
Developmental Vulnerability to Enhanced RTK
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myoblast migration in a non-cell autonomous manner, leading to a drastic reduction of limb
muscles. In contrast, enhanced Met signalling in myogenic cells themselves does not interfere
with their migration or with limb muscle development. Vulnerability of limb mesenchyme is
due to altered HGF bioavailability in the limbs, as assessed by functional studies. Together, our
findings show that the accomplishment of developmental programs in a genetic setting with
enhanced Met levels is ensured by the robustness of cell competence to buffer increased RTK
activity and to conserve functional downstream signalling. These findings also indicate that
developmental programs are sensitive to alterations in the spatial distribution of RTK action.
Results
Modelling enhanced wild-type Met signalling during mouse
embryogenesis
We have previously reported the generation of the Rosa26LacZ-stop-Met (R26stopMet) mice, which
allow Met levels to be enhanced in a temporal and spatial regulated manner, and have used
them to demonstrate that boosting neuronal RTK signalling delays disease onset in an amyo-
trophic lateral sclerosis animal model [24]. In the present study, we used the R26stopMet mice to
explore genetically the robustness of developmental programs following enhanced wild-type
RTK expression. To enhance Met-RTK signalling levels in all developing tissues, we crossed
R26stopMet mice with Tg(CMV-cre)1Cgn/J transgenics (namely Deleter-Cre) [26] thus obtaining
Deleter-Cre;R26Met mice/embryos (referred to as Del-R26Met) in order to excise the LacZ-stop
cassette in every cells and allow ubiquitous expression of the Met transgene (Mettg; S1A Fig). β-
galactosidase staining on whole mount or section of E10.5 embryos, used as readout of absence
of recombination, showed a spectrum of recombination in Del-R26Met embryos ranging from
cases with only residual staining compared to R26stopMet controls (defined as fully recombined
Del-R26Met embryos) to cases with a mosaic and more pronounced staining (defined as par-
tially recombined Del-R26Met embryos; S1B–S1D Fig). These findings show that the Deleter-
Cre line permits excision of the LacZ-stop cassette in all embryonic cell types, although with a
variable efficiency. This mosaicism is in part due to the random X-chromosome inactivation in
females, as the Cre transgene is X-linked [26]. In the present studies we only used fully recom-
bined Del-R26Met embryos. Whole mount in situ hybridization (ISH) with a humanMet probe,
distinguishing the Mettg from the endogenous mouse Met (mMet), showed ubiquitous expres-
sion of Mettg in fully recombined Del-R26Met embryos compared to controls (S2 Fig). To fur-
ther validate that this approach leads to enhanced Met signalling, we investigated the extent of
Met activation in developmental tissues by following its phosphorylation state using anti-phos-
pho-Met and anti-human Met antibodies in immunohistochemistry (IHC). Whereas Mettg
appeared to be uniformly expressed in most organs in Del-R26Met embryos, phospho-Met
staining was detected in restricted cell types (S3 Fig). These findings indicate the existence of a
restricted “competence map” for Met activation.
Highly recombined Del-R26Met neonates were identifiable at birth because of their hyper-
flexed forelimbs and weak hindlimbs (Fig 1A). Forelimb sections stained with MF20 antibod-
ies, which recognise the myosin heavy chain II, revealed that Del-R26Met limbs were almost
devoid of extensor muscles on their dorsal side, and exhibited a strong reduction of flexor mus-
cles in the ventral side, compared to controls (Fig 1A). This unbalance between antagonist
muscles leads to a pronounced wrist flexure. Whole mount ISH with aMyoD probe at E12.5
revealed a strong reduction of dorsal limb forming muscles in Del-R26Met mutants compared
to controls, whereas other sites ofMyoD expression were normal (Fig 1B). Next, we crossed
Del-R26Met mice with theMlc3f-2E-nlacZ transgenic mouse line, in which reporter gene
expression is driven by the murineMlc3f promoter and by theMlc1f/3f-3’ skeletal muscle
Developmental Vulnerability to Enhanced RTK
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Fig 1. Ubiquitously excess wild-type Met in developing embryos results into hyperflexed forelimbs.
(A) Top: Del-R26Met and control P0 mice showing hyperflexed limbs in mutants. Bottom: anti-myosin heavy
chain II IHC using MF20 antibodies on forelimb transversal sections of P0 Del-R26Met and control mice at the
level of the forearm showing almost absence of extensor (asterisk) and a great reduction of flexor
Developmental Vulnerability to Enhanced RTK
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enhancer [27]. In this mouse line, nLacZ (encoding nuclear β-galactosidase) is expressed in all
skeletal muscles throughout development, permitting visualisation of muscle formation in fully
recombined Del-R26Met embryos that no longer express the LacZ-stop cassette. Whole mount
staining showed that β-galactosidase activity was drastically reduced in Del-R26Met developing
limbs compared to controls (Figs 1C and S4).
Intriguingly, the limb phenotype of the Del-R26Met mice is reminiscent of the phenotype we
reported inMetgrb2/grb2,Met2P/2P, andMet2S/2S specificity-switch signalling mutants [18, 23,
28]. In theseMet signalling mutants, Met-dependent migration of myoblasts is severely com-
promised, leading to a reduction of limb muscles more pronounced in the dorsal than in the
ventral limb compartment [18, 23, 28]. We therefore assessed whether the development of
migrating myoblasts was also compromised in Del-R26Met mice. We addressed this issue using
distinct markers of the myogenic program [29]. Whole mount ISH on E10.5 embryos using
Lbx1 and Pax3 probes revealed a drastic reduction of migrating myoblasts from the somites
towards the limbs, with only few dispersed migrating cells left in Del-R26Met embryos com-
pared to controls (Fig 2A and 2B). Quantification of the ISH signal throughout the limbs
revealed approximately 90% reduction of migrating myoblasts in Del-R26Met forelimbs com-
pared to controls (Fig 2C and 2D). Impaired migration of myoblasts towards the tongue was
also found in Del-R26Met embryos (Fig 2A and 2B), indicating that ubiquitous expression of
the Mettg also compromises the developmental program of these migrating myoblasts.
Together, these findings show that ubiquitously enhancing wild-type Met-RTK specifically
interferes with the limb muscle developmental program by perturbing myoblast migration.
Enhanced wild-type Met expression is permissive in migrating
myoblasts, but not in limb mesenchyme
The intriguing similarity of the limb muscle phenotype in gain-of-function Del-R26Met and in
loss-of-functionMet specificity-switch signalling mutants [18, 23, 28] could be interpreted in
two ways. One scenario could be that in myoblasts, the amount of Met signalling must be quali-
tatively and/or quantitatively maintained within a narrow range. If the signalling level is
reduced (as inMet specificity-switch signalling mutants) or enhanced (as in Del-R26Met
mutants), the migration program may not occur. Alternatively, exogenous Met expression
might act in limb mesenchymal cells by altering their permissiveness to invading myoblasts. To
discriminate between these two possibilities, we selectively enhanced Met expression in either
migrating myoblasts or in limb mesenchyme, using the Pax3-Cre knock-in or the Prx1-Cre
transgenic lines, respectively [30, 31]. Consistently, whole mount ISH in Prx1-R26Met and
Pax3-R26Met mutants confirmed that expression of theMettg is adequately targeted to Prx1 and
Pax3 expression domains, respectively (Fig 3A and 3B). Whole mount ISH with Lbx1 and Pax3
probes unequivocally revealed a significant impairment in myoblast migration in Prx1-R26Met,
but not in Pax3-R26Met mutants (Figs 3C, S5A and S5B). Quantification analyses revealed
approximately 50% reduction of limb myoblasts in Prx1-R26Met mutants compared to
Pax3-R26Met and control embryos (Figs 3D, S5C and S5D). At E12.5, limb-forming muscles
were reduced in Prx1-R26Met, but not in Pax3-R26Met embryos, as revealed byMyoD ISH (S5E
Fig), even though the severity of this phenotype appeared less pronounced compared to earlier
stages. Finally, Prx1-R26Met mice showed hyperflexed forelimbs and weak hindlimbs at birth
(arrowhead) muscle mass in mutants. (B, C) Whole mount ISH withMyoD probe of E12.5 embryos (B) and β-
galactosidase staining of E11.5 embryos (C) showing that developing appendicular muscles are reduced in
Del-R26Met embryos (limbs are outlined in panels). The arrowhead in bottom panel B indicates developing
ventral limb muscles (flexor). Scale: 500μm.
doi:10.1371/journal.pgen.1005533.g001
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(S5E Fig; 90%, n = 16), whereas Pax3-R26Met mutants were indistinguishable from controls.
Together, these results disqualify myoblasts and identify limb mesenchymal cells as the cell
type in which enhanced Met signalling acts to disrupt myoblast migration. This suggests that
myoblast migration towards limb mesenchyme is impaired when exogenous Met expression
overlaps with the endogenous source of HGF.
The myoblast migration defect in Prx1-R26Met mutants underlines the importance of spatial
restriction of Met expression during development. We therefore asked whether alteration of
the regionalised distribution of Met also interferes with the molecular program regulating limb
patterning and skeletal morphogenesis. We followed expression of Shh and Fgf8, two major
regulators of early limb patterning and growth, and found no obvious defects in Del-R26Met
mutants compared to controls at E10.5 (S6A Fig). Furthermore, skeletal staining analyses did
not reveal any major defects in bone and cartilage formation in Del-R26Met forelimbs at birth
Fig 2. Myoblast migration is impaired inDel-R26Metmutants. (A, B) Whole mount ISH of E10.5 embryos with Lbx1 (A) and Pax3 (B) probes showing
drastic reduction of migrating myoblasts towards the developing tongue (arrowhead), fore and hind limbs. Bottom panel reports an enlargement at forelimb
levels. (C, D) Quantification analyses of Lbx1 (C) and Pax3 (D) positive domains in forelimbs. Left panels: each plot represents the average signal distribution
along the white line in forelimbs. Right panels: quantifications and statistical analyses of the sum of signal intensity based on intensity plots in left panels.
Numbers of samples for Lbx1: control, n = 13; Del-R26Met, n = 4; for Pax3: control, n = 11; Del-R26Met, n = 8. The sum of Pax3 signal intensity was calculated
between point A and B: A indicating a fixed position between the somites and the limb whereas B being placed at a fixed distance from A. Note almost lack of
signal in Del-R26Metmutants. Scale: 500μm. Mann-Whitney and Student-t test.
doi:10.1371/journal.pgen.1005533.g002
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Fig 3. Ectopic Met in limbmesenchyme drastically reduces limb colonization by migratingmyoblasts.
(A, B) Whole mount ISH using the humanMet probe showing the domain with Cre recombinase activity in
Prx1-R26Met (A) and Pax3-R26Met (B) embryos. Note that: a) in Prx1-R26Met embryos, the expression of the
Mettg (detected by hMet probe) is restricted in forelimbs; b) in Pax3-R26Met embryos,Mettg expression is
found in Pax3-positive territories. (C) Whole mount ISH of E10.5 embryos with the Lbx1 probe showing
drastic reduction of migrating myoblasts in the forelimbs of Prx1-R26Met, but not of Pax3-R26Metmutants.
Note that intact migration of myoblasts towards the forming tongue (arrowhead) in Prx1-R26Metmutants
correlates with the restricted expression of enhanced Met in limb mesenchyme. Bottom panel reports an
enlargement at forelimb levels. (D) Quantification analyses of Lbx1 positive domain in forelimbs. Left panels:
each plot represents the average signal distribution along the white line in forelimbs. Right panel:
quantifications and statistical analyses of the sum of signal intensity based on intensity plots in left panels.
Numbers of samples for Lbx1: control, n = 13; Prx1-R26Met, n = 4; Pax3-R26Met, n = 5. Note the reduced Lbx1
level in Prx1-R26Metmutants. Mann-Whitney and Student-t test.
doi:10.1371/journal.pgen.1005533.g003
Developmental Vulnerability to Enhanced RTK
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(S6B Fig). Together, these findings highlight the robustness of limb skeletal patterning pro-
gram, ensured by the intercalation of multiple signalling components, which does not permit
interference by ectopic Met.
We next analysed whether alteration of the regionalised distribution of Met leads to molecu-
lar changes in limb buds by following mainly the expression levels of cell surface proteins such
as heparan-sulfate proteoglycans (HSPGs), glypicans [32–34] and syndecans [35], which act as
gatekeepers of cellular responses by modulating extracellular signal distribution and perception
by targeted cells. We also analysed the expression levels of HSPG modifiers, such as Notum,
Hst2st1, andHst3st1 [36–38]. Among these candidates, some have been previously reported to
also modulate HGF signalling [39–41] or to be regulated by HGF/Met [42–44]. We also ana-
lysed Sdf1 levels for its cooperative function with Met signalling to control myoblast migration
[45]. A total of 12 genes were screened: the 6 Glypicans, Syndecan3 and 4,Hst2st1, Hst3st1,
Notum, and Sdf1. To analyse the expression levels of these genes, E10.5 forelimbs dissected
from Del-R26Met mutants and controls were used for qRT-PCR. Studies were restricted to
embryos that showed low levels of β-galactosidase activity in the whole body as a read-out of
efficient activation of the Mettg (see S1 Fig). We first assessed the sensitivity of this approach in
detecting molecular changes possibly occurring in a limited number of cells within the limb. In
particular, we quantified transcript levels of Pax3 and mouseMet, both expressed in migrating
myoblasts, and consistently found a drastic reduction in their mRNA levels in Del-R26Met
limbs compared to controls (Fig 4). Second, we confirmed a switch in LacZ versusMettg
expression in control and Del-R26Met limbs (S7A Fig). We next screened the 12 selected candi-
dates by comparing their expression levels in control versus Del-R26Met limbs. No significant
changes were observed in the expression levels of all Glypicans, of Syndecan3,Hst2st1, Hst3st1,
and Sdf1 (S7B and S7C Fig). In contrast, we found that expression levels of Notum and Synde-
can4 were significantly reduced in Del-R26Met versus control limbs (Fig 4). We next asked
whether such molecular differences in Del-R26Met mutants resulted from the depletion of limb
myoblasts, or reflected expression changes in limb mesenchyme. To address this question, we
took advantage ofMet loss-of-function mutants (MetLacZ/d(neo)), in which limbs are also devoid
of migrating myoblasts (S8 Fig), but where no specific changes in limb mesenchyme can be
expected [18, 22]. Consistently, Pax3 and mouseMetmyoblast-specific transcripts were also
absent fromMetLacZ/d(neo) mutant limbs (Fig 4). In contrast, the expression levels of Notum and
Syndecan4 (changed in Del-R26Met limbs) were similar inMetLacZ/d(neo) and control limbs (Fig
4). Altogether, these results exclude that downregulation of Notum and Syndecan4 in Del-
R26Met limbs is a consequence of lack of migrating myoblasts, and identify them as molecular
changes caused by Met expression in limb mesenchyme.
Met-expressing myoblasts are capable of buffering enhanced wild-type
Met levels
The intact myoblast migration in Pax3-R26Met mutants could reflect either the robustness of
the migration response to increased activation levels of Met intracellular effectors or an intrin-
sic capability of cells to restrain Met-RTK input. By performing IHC on embryo sections, we
followed Met signalling levels in control and mutant forelimbs at E10.5, when myoblast migra-
tion occurs. In myoblasts, levels of pTyr1234–1235-Met were enhanced in Del-R26
Met (non-
migrating cells blocked at the base of the limb) and Pax3-R26Met (migrating cells progressing
within the limb) compared to controls, whereas no major changes were observed in
Prx1-R26Met (where non-migrating myoblasts are also blocked in a proximal position in the
limb) (Figs 5 and 6A). By exploring the activation levels of two Met effectors, we found that the
phosphorylation levels of Akt and ERKs were comparable in control, Del-R26Met, Pax3-R26Met,
Developmental Vulnerability to Enhanced RTK
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and Prx1-R26Met myoblasts, despite high levels of phospho-Met in Del-R26Met and Pax3-
R26Met (arrows in Fig 5 and Fig 6B) Together, these results show that myoblasts have the
competence to buffer enhanced Met levels. In contrast, in limb mesenchymal cells levels of
phospho-Met were slightly increased in Del-R26Met and Prx1-R26Met when compared to con-
trol and Pax3-R26Met embryos (Figs 5 and 6A). This is best seen by comparing levels in areas
devoid of myoblasts even in control embryos (arrowheads in Fig 5 and “distal mes” boxes in
Fig 6A). This was accompanied by an increase in the phosphorylation levels of Akt and more
moderately of ERKs (Figs 5 and 6B). These findings indicate that limb mesenchymal cells lacks
the capacity to buffer an ectopic Met activation, which in turn causes defects in myoblast
migration.
Restriction of enhanced Met signalling occurs at distinct levels as
revealed by biochemical studies in embryonic hepatocytes
We next explored how buffering of enhanced Met signalling occurs in cells. Because of techni-
cal difficulties in isolating and establishing primary myoblast cultures from E10.5 embryos
for quantitative western blot studies, we addressed this issue using primary embryonic hepato-
cytes in which endogenous Met is expressed and required for their survival, as shown through
our earlier studies ofMet signalling mutants [18, 28, 46–48]. Primary embryonic hepatocyte
Fig 4. Ectopic Met in limbmesenchyme down-regulates the expression levels ofNotum and Syndecan4. qRT-PCR analysis of transcript levels of
mouseMet (mMet), Pax3,Notum, and Syndecan4 (Sdc4) in controls (ctrl; n = 11),Del-R26Met (Del-Met; n = 11),MetLacZ/d(neo) (KO; n = 7). Each dots
corresponds to transcript levels in forelimbs of E10.5 individual embryos (done in triplicate). Columns correspond to the average value, expressed asmean ± s.
e.m. Note: downregulation ofmMet and Pax3 inDel-R26Met andMetLacZ/d(neo)mutants compared to control, consistent with lack of migrating myoblasts;
downregulation ofNotum and Syndecan4 inDel-R26Metmutants compared to control, whereas no significant changes were found inMetLacZ/d(neo)mutants.
Mann-Whitney and Student-t test.
doi:10.1371/journal.pgen.1005533.g004
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Fig 5. Enhanced Met expression levels inDel-R26Metmyoblasts does not perturb activation of
downstream signalling effectors. Limb transverse sections of E10.5 control and Del-R26Met embryos
Developmental Vulnerability to Enhanced RTK
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cultures were established from E15.5 R26stopMet and Del-R26Met embryos and used to follow
biochemical changes in the Met signalling cascade. As expected, Del-R26Met embryonic hepato-
cytes express the Mettg, but not the β-galactosidase (in the stop cassette; Fig 7A). Total Met pro-
tein levels in R26stopMet and Del-R26Met primary embryonic hepatocytes were assessed by using
the Met25H2 antibodies generated against a synthetic peptide containing the amino acids sur-
rounding the Tyr1234–1235 within the kinase domain (recognising human and mouse Met).
Quantification of the Met25H2 levels revealed an approximately 4-fold increase of total Met pro-
tein amount in Del-R26Met versus R26stopMet controls. Increased levels of Met proteins correlate
with a concomitant increase in Met phosphorylation levels on Tyr1234–1235 (critical for Met
kinase activation; visualized with an antibody recognising mouse and human phosphorylated
Met), which are not further enhanced upon HGF stimulation (Fig 7A). We found two intrigu-
ing aspects of enhanced Met expression on downstream components of the Met signalling cas-
cade. Concerning Gab1, a cytoplasmic protein directly recruited by Met and functioning as a
platform for Met effectors, we found that: a) it was already phosphorylated in Del-R26Met cells
to a level comparable to that of control cells upon HGF stimulation, b) its phosphorylation lev-
els in Del-R26Met cells was not further enhanced upon HGF stimulation (Fig 7A). Concerning
further downstreamMet effectors such as Akt, Stat3, and ERKs, we found that their phosphor-
ylation levels increased upon HGF stimulation with comparable kinetic profiles in Del-R26Met
and control cells (Fig 7A). These findings indicate that the constitutive enhancement of Met
expression and phosphorylation on Tyr1234–1235 in hepatocytes does not result in a constitutive
activation of downstream signalling components.
To get insights into how enhanced Met signalling is restricted in embryonic cells, we ana-
lysed the phosphorylation levels of two other tyrosine residues implicated in receptor signalling
and endocytosis. Intriguingly, we found basal levels of Met phosphorylation on Tyr1003 (critical
for Met protein ubiquitination and degradation) and on Tyr1349 (one of the two multifunc-
tional docking sites required for Met signalling), which were enhanced upon HGF stimulation
(Fig 7B). Consistently, Met and Gab1 phosphorylation was impaired in the presence of the Met
inhibitor PHA665752 (Fig 7C). Thus, basal levels of Met phosphorylation in mutant embry-
onic hepatocytes appear sufficient to initiate signalling activation (e.g. Gab1 phosphorylation
on Tyr627), but not to propagate signalling activation to downstream pathways (e.g. Akt, Stat3,
ERKs). Together, these findings indicate that the Mettg achieves its full signalling competence
following a burst of HGF stimulation.
Gain of wild-type Met expression in limb mesenchyme does not perturb
expression pattern and levels of its ligand HGF, but its bioavailability
As the domain of Prx1-cre activity in the limb encompasses the source of HGF exerting che-
moattraction on migrating myoblasts, we next asked whether ectopic Met in these cells alters
the bioavailability of HGF to migrating cells. ISH and IHC analyses revealed no significant dif-
ferences on HGF expression patterns or levels between Del-R26Met and control embryos (Fig
8A, 8B and 8C), ruling out the possibility that ectopic Met alters Hgf gene expression and HGF
protein production in limb mesenchyme. Moreover, we found comparable protein levels of
uncleaved HGF in E10.5 Del-R26Met and control forelimbs (Fig 8D) as well as unchanged
showing the distribution of phospho-Met (on Tyr1234–1235), phospho-Akt, phospho-ERKs (red) and of Pax3
protein (green) in myoblasts. Note ectopic phospho-Met in limb mesenchyme (arrowheads) and in non-
migrating myoblasts (arrows) in Del-R26Metmutants. Asterisks indicate non-specific staining in blood cells.
Scale: 100μm.
doi:10.1371/journal.pgen.1005533.g005
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Fig 6. Immunohistochemical analysis showing that myoblasts possess a buffering competence to
enhanced Met levels. (A) Limb transverse sections of E10.5 control, Prx1-R26Met, and Pax3-R26Met
embryos showing the phospho-Met (red) and Pax3-positive myoblasts (green). Note ectopic phospho-Met in
limb mesenchyme of Prx1-R26Met and in migrating myoblasts of Pax3-R26Metmutants. Few migrating
myoblasts are present in limb mesenchyme of Prx1-R26Metmutants. White boxes indicate the position of
enlargements shown in panel B. Yellow boxes indicate distal mesenchyme (distal mes) area devoid of
myoblasts where enhanced phospho-Met signal is detected in Prx1-R26Metmutants. (B) High magnification
of limb transverse sections showing phosphorylation levels of Met, Akt, and ERKs (red) in migrating
myoblasts (Pax3-positive; green) of E10.5 control, Prx1-R26Met, and Pax3-R26Met embryos. Note that despite
the high phospho-Met levels in Pax3-R26Metmutants, no major changes are observed in phospho-Akt and
phospho-ERKs when compared to controls and Prx1-R26Metmutants. For Prx1-R26Metmutants, two areas
are shown: square 1 indicates few migrating myoblasts; square 2 indicates mesenchyme devoid of
myoblasts. Asterisks indicate non-specific staining in blood cells. Scale: 100μm.
doi:10.1371/journal.pgen.1005533.g006
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mRNA levels of urokinase-type plasminogen activator (Plau), an enzyme involved in HGF pro-
cessing (Fig 8E).
Next, we investigated whether Met expression in mesenchymal territories would alter HGF
bioavailability. For this purpose, we established primary embryonic mesenchymal cell cultures
from E10.5 forelimbs and biochemically assessed their competence to respond to HGF stimula-
tion. As expected, control limb mesenchymal cells did not respond to HGF stimulation, consis-
tent with the fact that these cells do not express the receptor (Fig 8F). In contrast, we found
high levels of Met phosphorylation on Tyr1234–1235 in Del-R26
Met limb mesenchymal cells (Fig
8F). HGF stimulation induced Gab1 phosphorylation and enhanced the basal levels of Akt and
ERKs phosphorylation (Fig 8F). Furthermore, treatment with anti-HGF blocking antibodies
drastically reduced the phosphorylation levels of Met in Del-R26Met limb mesenchymal cells,
thus showing that HGF is indeed produced by these cells and that basal Met phosphorylation is
due to endogenous HGF in these culture conditions (Fig 8F). Finally, we biochemically ana-
lysed the levels of HGF in conditioned media of Del-R26Met limb mesenchymal cells and found
that levels of uncleaved HGF were comparable to those of control cells (S9A Fig).
To explore whether the HGF released by control and Del-R26Met cultures was bioactive, we
co-cultured MDCK cells with E10.5 dissociated limb mesenchymal cells as a source of HGF
Fig 7. Biochemical analyses in embryonic hepatocytes show restriction of enhancedMet signalling at
distinct levels. (A) Western blot analyses of total protein extracts of E15.5 primary embryonic hepatocytes
derived from R26stopMet (containing the LacZ-stop cassette therefore expressing the β-galactosidase) and
from Del-R26Met (after deletion of the LacZ-stop cassette, therefore expressing the transgenic Met detected
by anti-human Met antibodies) embryos. Analyses was performed before and after HGF stimulation
(50ng/ml). Note: a) similar levels of mouse Met in R26stopMet and Del-R26Met cells; b) high levels of Met
phosphorylation on Tyr1234–1235 in Del-R26
Met cells independently of HGF stimulation; c) comparable Gab1,
Akt, Stat3, and ERK phosphorylation levels upon HGF stimulation in R26stopMet and Del-R26Met cells; d)
despite Gab1 phosphorylation in untreated Del-R26Met cells in contrast to control R26stopMet cells, the
phosphorylation levels of Akt, Stat3, and ERK is unchanged. Actin protein levels were used as loading
controls in all western blot analyses. (B) Left: western blot analyses of total protein extracts of E15.5 primary
embryonic hepatocytes derived from Del-R26Met embryos. Note basal levels of Met phosphorylation on
Tyr1003 and on Tyr1349; phosphorylation levels are further increase upon HGF stimulation (50ng/ml). Right:
schematic representation of Met indicating the different tyrosine residues analysed by western blots. (C)
Western blot analysis of total protein extracts of E15.5 primary embryonic hepatocytes derived from Del-
R26Met embryos showing impaired phosphorylation of Met and Gab1 in the presence of the Met inhibitor
PHA665752 (PHA; 1μM).
doi:10.1371/journal.pgen.1005533.g007
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(Fig 9A). MDCK cells acquire a “scattered phenotype” upon HGF stimulation [49, 50], thus
providing an excellent readout of HGF bioavailability in conditioned media by limb mesenchy-
mal cells. To evaluate HGF bioavailability, we established an experimental setting in which
MDCK cells were co-cultured either with dissociated limb mesenchymal cells or with dissected
limbs (Fig 9A). HGF activity was quantified by scoring the percentage of MDCK clones exhib-
iting a dense phenotype (category I), an expanded phenotype (category II), or a scattered phe-
notype with some or several cells detached from the clone (category III; Fig 9B). A condition
with mesenchymal cells from two control forelimbs consistently triggered an efficient MDCK
Fig 8. Ectopic Met does not change the expression profile and levels of HGF in limbmesenchyme. (A)
Whole mount ISH of E10.5 control and Del-R26Met embryos withHgf probe showing comparable expression
domain in developing forelimbs. (B) Quantification analyses of Hgf positive domains in forelimbs. Left panels:
each plot represents the average signal distribution along the white line in forelimbs. Right panels:
quantifications and statistical analyses of the sum of signal intensity based on intensity plots in left panels.
Numbers of samples: control, n = 6; Del-R26Met, n = 6. Note no significant changes of signal in controls and
Del-R26Metmutants. (C) Immunofluorescence analysis of HGF (red) and Pax3 (green) proteins in transversal
sections of E10.5 control and Del-R26Met embryos at forelimb levels. Note the impaired myoblast migration
(Pax3-positive cells) in Del-R26Metmutants, whereas no significant changes are detected in HGF protein
levels. Asterisks indicate non-specific staining in blood cells. Scale: 100μm. (D) Western blot analyses of total
protein extracts of E10.5 control and Del-R26Met dissected forelimbs. Note comparable levels of uncleaved
HGF in Del-R26Metmutants despite the ectopic expression of Mettg and the enhanced phosphorylation levels
of Met and Gab1. (E) qRT-PCR analysis showing comparable Plau transcript levels in E10.5 dissected
forelimbs of control (ctrl; n = 11) and Del-R26Met (Del-Met; n = 11) embryos. (F) Western blot analysis of total
protein extracts of E10.5 forelimb mesenchymal cell cultures showing phosphorylation levels of Met, Gab1,
Akt, and ERKs in control and Del-R26Met cultures, in cells untreated, stimulated with HGF (H) or in the
presence of anti-HGF blocking antibodies (αH).
doi:10.1371/journal.pgen.1005533.g008
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scattering response (Fig 9C). MDCK scattering response triggered by conditioned media from
control limb mesenchymal cells was drastically reduced in the presence of Met inhibitors
(PHA665752, cryzotinib, or SU11274: 1μM; Fig 9C) or of anti-HGF blocking antibodies (anti-
HGF: 30μg/ml; Fig 9D). In contrast, we found a drastic reduction in the percentage of MDCK
colonies with a scattered phenotype using mesenchymal cells from two Del-R26Met forelimbs
(Fig 9E). Similar results were obtained using MDCK cells directly co-cultured with E10.5
Fig 9. Ectopic Met in limbmesenchyme alters HGF bioavailability. (A) Scheme illustrating the experimental procedure employed for evaluating through
MDCK cell scattering the bioavailability of HGF from control and Del-R26Metmutant limb mesenchymal cells or from dissected forelimbs. The scheme
indicates the experimental procedure applied for collecting media conditioned by limb mesenchymal cells for biochemical analysis (top; shown in S9A Fig),
for MDCK scattering assays using co-cultures with limb mesenchymal cells (middle; shown in Fig 9C, 9D and 9E) or with dissected limbs (bottom; shown in
S9B Fig). (B) Pictures of MDCK colonies showing the three categories that were defined to determine the extent of cell contact and spreading for
quantification studies of scattering response. (C) Quantitative analysis of MDCK cell scattering in co-cultures with control limb mesenchymal cells in the
absence (no) and in the presence of the Met inhibitor PHA665752 (PHA; 1μM), cryzotinib (Cryzo; 1μM), or SU11274 (SU; 1μM). (D) Quantitative analysis of
MDCK cell scattering in co-cultures with control limb mesenchymal cells in the absence (no) and in the presence of the anti-HGF blocking antibodies (anti-
HGF; 30μg/ml). (E) Quantitative analysis of MDCK cell scattering in co-cultures with control or Del-R26Met limb mesenchymal cells. Note a drastic reduction
in the scattering response when MDCK cells are co-cultured with Del-R26Metmutant cells (control: n = 4; Del-R26Met: n = 3). Mann-Whitney and Student-t
test.
doi:10.1371/journal.pgen.1005533.g009
Developmental Vulnerability to Enhanced RTK
PLOSGenetics | DOI:10.1371/journal.pgen.1005533 September 22, 2015 16 / 29
forelimb explants (S9B Fig). Together, these findings indicate that although ectopic Met
expression in limb mesenchyme does not alter HGF expression pattern or levels, it impairs bio-
availability of HGF from mesenchymal cells.
Discussion
The events that cells experience overtime shape progressively their intrinsic capability to
respond and to integrate RTK inputs. Our data illustrate that enhanced wild-type RTK signal-
ling is differentially interpreted by cells according to their competence and the robustness of
developmental programs they undergo. Most developing cell types appear insensitive to
changes in Met expression either because enhanced Met protein levels is not followed by its
activation (e.g. in the absence of ligand), or because it is neutralized by the action of other sig-
nals acting on cells. This is not the case of migrating myoblasts that, although insensitive them-
selves to enhanced Met expression, failed to migrate towards the limb buds as a result of
ectopic Met expression in mesenchymal cells. Ectopic Met in the mesenchyme perturbs tran-
scriptional regulation of some genes and interferes with HGF bioavailability, thus rendering
the mesenchyme non accessible to myoblasts (Fig 10). Our results demonstrate that whereas
most cell types during development are capable of handling moderate perturbations in RTK
signalling levels, certain cell types are vulnerable to alterations in changes of spatial RTK
action.
Cell competence to Met activation
The strategy of using the wild-type Met-RTK, rather than constitutive active forms, to generate
Del-R26Met mice has enabled expression of the receptor at more physiological levels. A moder-
ate increase in Met levels during development drastically affects limb muscle formation by per-
turbing myoblast migration. Although we cannot exclude subtle phenotypes in other
developing organs, these results highlight the restricted sensitivity of the myoblast migration
process to ectopic Met in limbs. We genetically demonstrate that myoblasts themselves are not
susceptible to enhanced Met signalling levels for their migration, when gain of expression is
achieved in the myogenic lineage with Pax3-Cre. This context contrasts with a genetic setting
in which Pax3 gain-of-function triggers ectopic myoblast delamination and migration at non-
limb somite levels, caused by Met over-expression [51]. It is therefore tempting to propose the
existence of a threshold level of sensitivity to enhanced Met signalling for migrating myoblasts:
Met signalling is enhanced below this level in Del-R26Met, thus failing to elicit any qualitative
change in myoblast behaviour, whereas Met signalling is enhanced above this threshold in
Pax3 gain-of-function mutants, thus triggering ectopic delamination. However, it is also possi-
ble that the effects of Pax3 gain-of-function mutants involve missregulation of other Pax3 tar-
get genes. TheMet specificity-switch mutants have previously revealed that myoblast
migration is impaired by lowering qualitative and/or quantitative Met signalling levels [18, 28].
Thus, findings from the present studies together with those discussed here highlight the exis-
tence of a precise window of Met signalling compatible with proper myoblast migration: within
this window, cells can buffer fluctuations in RTK signalling input to avoid changes in qualita-
tive output. This also implies that myoblasts are competent to read Met signalling for proper
migration within a defined quantitative range.
Modulating HGF bioavailability in limb mesenchyme for muscle
patterning
Our studies also uncover another intriguing aspect linked to myoblasts migration: their suscep-
tibility to alterations in the spatial distribution of Met expression. The limb mesenchyme is a
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local source of HGF exerting a chemoattractant effect on myoblasts that migrate from the
somites. In a wild-type context, migrating myoblasts experience a territory devoid of Met-posi-
tive cells along their path. Our results ruled out that ectopic Met would act by altering the HGF
mRNA and protein expression levels in limb mesenchyme. Instead, they provide evidence that
Fig 10. Schematic representation summarizing the different molecular and phenotypic effects of enhancedMet expression in myoblasts and limb
mesenchymal cells. In a wild-type context (top), limb mesenchymal cells secrete HGF required for migration of myoblasts towards the limb buds. Enhanced
expression of Met in myoblasts (as assessed in Pax3-R26Met embryos; middle) does not alter their migration due to a buffering event: the activation levels of
signalling effectors such as ERKs and Akt are restrained despite enhanced Met phosphorylation. The size of each signal is representative of their
phosphorylation levels. Limb mesenchymal cells are vulnerable to ectopic Met expression (as assessed in Prx1-R26Met embryos; bottom), illustrated by
changes in gene expression, by failure of HGF bioavailability, and by myoblast migration defects. Alteration of HGF bioavailability can be due to: 1)
upregulation of a negative interactor that would interfere with the capacity of HGF to bind/activate Met (indicated as “HGF inhibitor”), 2) downregulation of a
HGF interactor acting as enhancer of its bioactivity (indicated as “HGF activator”), 3) expression of a chemorepellent factor that renders limb mesenchyme
inaccessible to migrating myoblasts, or 4) HGF titration by ectopic Met in mesenchymal cells (indicated as “HGF trapping”).
doi:10.1371/journal.pgen.1005533.g010
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limb mesenchyme must be devoid of Met expressing cells to ensure normal HGF bioavailabil-
ity. Although we cannot fully exclude that ectopic Met acts by titrating the HGF secreted by
limb mesenchyme, a series of experimental arguments make this possibility unlikely. Compara-
ble levels of HGF protein were found in conditioned media from control and Del-R26Met limb
mesenchymal cells, in spite of reduced scattering-induced activity, indicating that HGF secre-
tion and release is not impaired by the occurrence of autocrine HGF/Met binding. Moreover,
an event of HGF trapping by Met should recapitulate all developmental defects observed in
Met loss-of-function mutants. Although the molecular mechanism remains to be identified, it
is tempting to speculate that defects in HGF bioavailability could be linked to transcriptional
and/or posttranscriptional changes caused by ectopic Met in limbs. This possibility is sup-
ported by our data showing signalling (e.g. phospho-Met, phospho-Gab, and phospho-ERKs
upregulation) and transcriptional (e.g. Notum and Syndecan4 downregulation) changes occur-
ring in mutant limbs compared to controls. Thus, ectopic Met expression and activation in
limb mesenchyme triggers a number of qualitative responses that cannot be buffered by cells.
Our co-culture studies highlight a difference in HGF bioavailability, which could result from a
change in expression levels of a modulator of HGF, such as either the downregulation of a
HGF interactor acting as enhancer of HGF bioactivity, or the upregulation of a negative inter-
actor that would interfere with the capacity of HGF to bind/activate Met (Fig 10). Among posi-
tive modulators, it has been shown that Glypican1 regulates HGF/Met-triggered migration of
C2C12 myoblasts [52], Syndecan4 is expressed together with Met in adult satellite cells where it
contributes to muscle regeneration [53, 54], and Glypican4 sustains HGF-mediated branching
morphogenesis [39]. Alternatively, mutant cells could express a chemorepellent factor that
would render the limb mesenchyme inaccessible to migrating myoblasts (Fig 10). The identifi-
cation and the functional validation of the molecular mechanism(s) responsible for the non-
cell autonomous defect of myoblast migration in Del-R26Met mutants is highly challenging, as:
1) a putative HGF modulator could be altered at the level of transcription, post-transcription,
and/or secretion; 2) modulators of chemoattractants do not exert an “on or off” action, but
rather fine tune signalling mechanisms, and may act redundantly with one another; 3) distinct
mechanisms could cooperate to cause this qualitative phenotype, each of them participating
although with a variable quantitative extent.
Robustness versus sensitiveness of developmental programs to
fluctuation on RTK signalling levels
By using motor neurons as a cellular paradigm, we have provided examples of robustness ver-
sus sensitivity to RTK signalling in developmental outcomes [22, 23]. We have shown that a
specific motor neuron pool requires HGF/Met for survival, hence for proper maintenance of
muscle innervation. In contrast, neighbouring Met-expressing motor neuron pools do not
depend on the action of HGF/Met for their survival, in spite of their early dependence for
motor neuron subtype specification and axon growth [22]. Furthermore, we have shown that
whereas HGF/Met-dependent motor neuron survival and fate specification is permissive to
substitutions of downstream signalling routes, nerve growth patterning is strictly dependent on
a selective, non-substitutable, pathway [23]. Intriguingly, signalling requirements for cell sur-
vival in motor neurons is different than those in hepatocytes [46–48], demonstrating how sig-
nalling requirements for RTK-triggered biological outcomes is refined by the type of cells.
Altogether, these results are consistent with the model whereby the degree of equivalence
between signalling cascades available to RTK-mobilisation within a developmental program
for a given biological outcome is refined in a cell type-dependent manner, thus determining
the degree of robustness versus sensitiveness to RTK signals according to cell competence.
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The present study further expands our knowledge on robustness versus sensitiveness of cells
in developmental processes with respect to subtle increases in RTK signalling. Besides the sen-
sitivity of myoblasts to changes in Met signalling in limb mesenchyme, most other develop-
mental processes appear robust and capable of buffering excess Met-RTK signalling (Fig 10).
How can most cells deal with RTK signalling perturbation? For cells with endogenous Met, one
possibility is that they can buffer the additional burst of RTK signalling by “considering” it as a
negligible quantity with respect to the overall signalling network operating in cells. Such buffer-
ing competence—or resilience—would be possible as long as this additional burst of RTK
occurs within a defined quantitative window. Our biochemical studies show that effectiveness
of the enhanced Met expression and activation is limited at different intracellular levels. A first
point of restriction occurs at the level of the receptor itself: although Mettg is fully phosphory-
lated on Tyr1234–1235 that are critical for its kinase activation, it only becomes fully signalling
competent after HGF stimulation, as shown by HGF-induced increased phosphorylation levels
on Tyr1003 and Tyr1349 implicated in receptor signalling and endocytosis and by activation of
Akt, STAT3, and ERKs. Thus, in Del-R26Met cells, HGF switches Met from a subthreshold sig-
nalling status into a fully signalling competent form. These results also show that the R26stopMet
mice represent a valuable genetic model to explore the consequences of moderate perturbations
of Met as its full signalling competence still depends on ligand stimulation. A second point of
restriction occurs at the levels of Gab1, which is phosphorylated at comparable levels in control
and Del-R26Met cells upon HGF stimulation. Notably, in the absence of HGF stimulation Gab1
is phosphorylated in Del-R26Met hepatocytes (also expressing endogenous Met), but not in Del-
R26Met mesenchymal cells (not expressing endogenous Met), indicating that the competence of
cells to restrict signalling of enhanced Met is different according to the cell type, and that this
competence can be influenced by factors such as expression levels of the receptor. Another
restriction occurs further downstream, as revealed by the comparable phosphorylation levels of
Akt, STAT3, and ERKs observed in control and Del-R26Met hepatocytes (by biochemical stud-
ies in culture) and myoblasts (by IHC in vivo). Such restrictions imply that different cell types
possess distinct mechanisms that sense and calibrate the level of activation required for and
compatible with biological programs. Overall, our studies provide additional insights into the
existence of an exquisite monitoring of signalling levels within cells to attenuate enhanced RTK
levels.
For cells that do not express endogenous Met, the issue of buffering an ectopic Met is only
relevant provided that cells possess the adequate co-factors and downstream effectors. When
they do, buffering may occur through mechanisms similar to those in cells with endogenous
Met. Whereas most territories/cell types with ectopic Met appear capable of resilience, the limb
mesenchyme is vulnerable to this signalling perturbation, illustrated by changes in gene expres-
sion, by failure of HGF bioavailability, and by resulting myoblast migration defects.
Conditional R26stopMetmouse model to enhance wild-type Met signalling
in skeletal muscle
The conditional R26stopMet mouse model represents a valuable tool for future studies on
whether and how enhanced Met signalling impacts muscle development at later time points
and during regeneration [55]. This issue is consistent with the persistence of Met expression in
migratory muscles even after completion of the migration process, as shown byMetLacZ/+
embryos at E13.5 (S8 Fig). The migration defect we report here may be clinically relevant as
failure of subsets of myoblasts to migrate properly might represent a developmental dysfunc-
tion at the root of some muscle pathologies. This link is nicely illustrated by our recent findings
showing that alterations of Fat1 are associated with Facioscapulohumeral dystrophy (FSHD)
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[56]. Loss of Fat1 in mice causes muscle shape defects resulting from altered migration polarity
of a selective group of muscles matching those affected in FSHD [56]. Fat1 expression is also
regulated by HGF/Met, by Pax3-FKHR, and by Lbx1 [42, 45, 57]. Alteration of Met signalling
can also impact muscle homeostasis by causing atrophy [58] and tumour formation. For exam-
ple, Met is overexpressed in rhabdomyosarcoma, where it contributes to invasive growth [57],
andMet gene amplification is frequently associated with sarcoma susceptibility in muscular
dystrophy mouse models [51]. Therefore, R26stopMet mice can be instrumental for future evalu-
ation of how Met signalling impacts on muscle physiology, regeneration, and/or pathologies.
Conclusion
The R26stopMet mice modelling conditional gain of RTK signalling exemplify robustness versus
sensitiveness of cells to signalling perturbations in order to ensure reproducible developmental
outcomes. The genetic approach we employed permits subtle changes in RTK signalling, in
contrast to others where constitutive RTK activation, either by point mutations or ligand over-
expression, leads to dramatic biological consequences. It is therefore not surprising that the
Del-R26Met mice do not recapitulate defects reported in other transgenics with an over-activa-
tion of the HGF/Met system. It is the case of mice in which HGF over-expression causes aber-
rant myoblast and neural crest migration, leading to ectopic muscle formation and melanosis
in the central nervous system [59, 60]. A number of transgenic mice have been instrumental to
demonstrate the capability of oncogenic forms of RTKs to trigger neoplasia. However, these
mice do not permit assessment of how cells perceive and handle moderate changes in RTK sig-
nalling overtime. The R26stopMet genetic setting represents therefore a suitable system to explore
the in vivo robustness of cells to subtle increase of RTKs signalling during tissue homeostasis as
well as during development and may disclose unexpected switches in cell sensitivity from
development to adulthood.
Materials and Methods
Ethics statement
All procedures involving the use of animals were performed in accordance with the European
Community Council Directive of 24 November 1986 on the protection of animals used for
experimental purposes (86/609/EEC). The experimental protocols were carried out in compli-
ance with institutional Ethical Committee guidelines for animal research (comité d’éthique
pour l’expérimentation animale–Comité d’éthique de Marseille; agreement number D13-
055-21 by the Direction départementale des services vétérinaires–Préfecture des Bouches du
Rhône).
Transgenic lines and genotype analysis
The generation of the R26stopMetmice (international nomenclature Gt(ROSA)26Sortm1(Actb-Met)Fmai)
carrying a conditional mouse–human chimericMet transgene into the Rosa26 locus was previ-
ously reported [24, 25]. The mouse lines expressing Cre recombinase under Prx1 [31] and
Pax3 [30] promoters, the Deleter-Cre [26],Mlc3F2E-LacZ transgenic [27], theMetd(neo/+) [18]
andMetLacZ/+ [22] mouse lines were previously described. Mice and embryos were genotyped
by PCR analysis of genomic DNA as reported in the above studies. For embryo collection,
embryonic days were counted considering midday post-coitum as E0.5. All procedures involv-
ing the use of animals were performed in accordance with the European Community Council
Directive of 24 November 1986 on the protection of animals used for experimental purposes
(86/609/EEC). The experimental protocols were carried out in compliance with institutional
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Ethical Committee guidelines for animal research (comité d’éthique pour l’expérimentation
animale–Comité d’éthique de Marseille; agreement number D13-055-21 by the Direction
départementale des services vétérinaires–Préfecture des Bouches du Rhône).
RNA in situ hybridisation and histological analysis
For ISH, embryos were collected in phosphate buffered Saline (PBS) and fixed in 4% parafor-
maldehyde (PFA) overnight. Whole mount RNA ISH done by using the relevant digoxigenin-
labeled RNA probes. X-Gal and Salmon-Gal staining were performed as previously described
[23, 24, 61]. For IHC of P0 limbs, newborns were embedded in cold glycol methacrylate (Tech-
novit 8100) for cryosections. Limbs were cut transversally (16μm) and processed for antibodies
staining as described [24]. For IHC at E10.5, embryos were embedded in paraffin, cut transver-
sally (10μm), and processed for antibodies staining as described [62].
MDCK scattering assays
Procedures were performed as described [49, 50]. Briefly, MDCK cells (ATCC, Rockville, MD)
were seeded in 96-well plates (for forelimb co-cultures; Corning, Acton, MA) or on coverslips
(for forelimb mesenchymal cells co-cultures) at 1250 cells/cm2 in DMEM containing 10% (v/v)
fetal bovine serum (FBS), 100U/mL penicillin, 100μg/mL streptomycin, 4mM L-glutamine,
and 1mM of sodium pyruvate. Cells were first incubated for 24 h at 37°C, in 5% CO2 to allow
attachment and colony formation. For forelimb co-cultures, plates were processed as followed.
In the first group, the media was changed with fresh media containing increasing concentra-
tions of recombinant human HGF (0.1, 0.3, 1, 3, 10, 30ng/ml; R&D) to estimate the bioactivity
dose of HGF released by wild-type limbs (comparable to 5ng/ml of recombinant human HGF).
In the second group, media was replaced and added together with freshly dissected 2 forelimbs
derived from E10.5 embryos of different genotypes (done by PCR using remaining tissue).
Twenty-four hours later, the MDCK cells were fixed with 4% PFA in PBS, then cells were
stained with Crystal violet. For quantification, at least 10 images with several cell colonies were
analysed. Three different categories were defined: category 1 corresponds to not-scattered colo-
nies; category 2 corresponds to colonies in which cells start losing their contact; category 3 cor-
responds to colonies with visible scattered cells.
Limb mesenchymal cell cultures
Forelimbs from E10.5 embryos were dissected in HBSS supplemented with 100U/mL penicil-
lin, 100μg/mL streptomycin, and 7mMHepes (Life Technologies) and incubated for 5 min in
2% trypsin (Sigma). Limbs from individual embryos were processed separately and a piece of
the body was used for genotyping. Then, trypsin was inactivated with DMEM supplemented
with 10% (v/v) FBS, 100U/mL penicillin, 100μg/mL streptomycin, 4mM L-glutamine, 1mM of
sodium pyruvate, and non-essential amino acids (defined as complete media). Cells were disso-
ciated by pipetting, then spin down for 5 min, resuspended in DMEM complete media, and
plated in 4 well plates (2 forelimbs per well). Cells were grown at 37°C in a humidified atmo-
sphere of 5% CO2. For biochemical analysis of conditioned media, after 48 hrs cells were
washed twice then cultured in DMEM complete media without serum for 24 hrs. For scattering
assays, after 48 hrs a coverslip with previously plated MDCK cells was placed upside down in
order to have MDCK cells in contact with media pre-conditioned by limb mesenchymal cells.
In order to avoid MDCK and limb mesenchymal cell contact, a spacer was added between the
plate and the coverslip. For HGF/Met inhibition, Met chemical inhibitors (cryzotinib,
PHA665752, and SU11274; 1μM; Selleckchem) or blocking anti-HGF antibody (30μg/ml;
Developmental Vulnerability to Enhanced RTK
PLOSGenetics | DOI:10.1371/journal.pgen.1005533 September 22, 2015 22 / 29
R&D) where added prior to co-culture with MDCK cells on coverslips. After 24 hrs co-cultures,
coverslips were fixed and processed as described above.
Western blots
Culture of primary embryonic hepatocytes were performed as previously described [28, 46–
48]. Protein extracts from embryonic hepatocytes and limb mesenchymal cells were prepared
and western blot (WB) analysis was performed as previously described [63, 64]. For biochemi-
cal analysis, conditioned media was collected, spin down to remove cellular debris, and then
incubated with either heparin-beads or lectin-beads (Amersham).
Antibodies
Antibodies used were from Cell Signaling: anti-Met 25H2 (1:2000 for WB), anti-phospho-
Tyr1234/1235-Met (1:2000 for WB; 1:50 for IHC), anti-phospho-Tyr1003-Met (1:2000 for WB),
anti-phospho-Tyr1349-Met (1:1000 for WB), anti-phospho-Tyr627-Gab1 (1:2000 for WB), anti-
phospho-Ser473-Akt (1:2000 for WB; 1:20 for IHC), anti-phospho-Ser727-Stat3 (1:2000 for
WB), anti-phospho-Thr202-Tyr204-ERKs (#9106; 1:10000 for WB), anti-phospho-Thr202-
Tyr204-ERKs (#4376; 1:150 for IHC), anti-ERKs (1:10000 for WB); from Santa-Cruz Biotech-
nology: anti-mouse Met (1:200 for WB), anti-human Met (1:1000 for WB), anti-HGF (1:500
for WB); from Abcam: anti-β-galactosidase (1:2000 for WB); from R&D: anti-mouseHGF
(1:50 for IHC); from Sigma-Aldrich: anti-actin (1:12000 for WB); from Assay Designs: anti-
human Met (1:500 for IHC); from hybridoma bank: Pax3 (1:10 for IHC), anti-myosin heavy
chain II (MF20; 1:50 for IHC); from Jackson: anti-rabbit IgG-peroxidase or anti-mouse IgG-
peroxidase (1:4000 for WB), anti-mouse fluorescent-coupled secondary antibodies (1:400 for
IHC), anti-mouse or rabbit biotin-coupled secondary antibodies (1:500 for IHC).
Quantitative RT-PCR analysis
Total RNA was isolated from embryos using the RNeasy Mini Kit (Qiagen, Valencia, CA)
according to manufacture instruction. cDNA was generated using the Reverse Transcription
Kit (Biorad). cDNA (30ng) was amplified by real time PCR using 4 μL SYBR Green qPCR
SuperMix-UDG with Rox (Biorad) and 2μL of forward and reverse primers (0.1 μM). The anal-
ysis was performed on each sample in triplicates using Applied Biosystems (Foster City, CA).
Relative transcript levels were calculated using the comparative Ct method and normalized to
the housekeeping gene GAPDH. Primer sequences are listed in S1 Table.
Skeletal staining
New-born mice were scarified and placed in water overnight at 4°C, then eviscerated, and skin
was removed. Samples were fixed in 96% ethanol overnight. Cartilage staining was performed
using alcian blue solution for 24 hours (0,15mg/ml alcian blue from Sigma in 1:4 volumes of
acetic acid glacial and 96% ethanol). Samples were then rinsed in ethanol 96% for 1 hour and
clearing was done for 6 hours in 2% KOH. Bone staining was performed using alizarin red
solution for 24 hours (0,07mg/ml alizarin red from Sigma in KOH 1%). Samples were treated
with 1% KOH/20% glycerol, then stored in glycerol/ethanol (1:1 volume).
Image processing and analyses
For whole mount ISH, quantification of signal intensity in limbs was performed using the Ima-
geJ software. Briefly, images were first converted to a grey scale and then inverted to a negative
scale (with the highest signal intensity matching being white and the lowest black). Signal
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intensity was measured along a horizontal line of a given pixel length (matching the forelimb).
After background and threshold subtraction, the values were averaged between several samples
of each genotype to generate an average signal distribution plot (considering left and right
limbs separately). The total signal intensity was also calculated for each sample and plotted
individually.
For Met25H2 and HGF protein levels, quantification of signal intensity was done on western
blots using the image J software. Images were process as described above. Values were averaged
between different samples.
Statistical analysis
Results were expressed as the mean ±SEM. Statistical significant differences were estimated by
applying unpaired t-Student test for data showing normal distribution and by Mann-Whitney
test otherwise. P values are indicated in Figs.
Supporting Information
S1 Fig. Strategy to ubiquitously enhance wild-type Met in developing embryos. (A) Sche-
matic representation of transgenic mice carrying the LacZ-stop cassette followed by chimeric
Met before (Rosa26LacZ-stop-Met, namely R26stopMet) and after Cre-mediated recombination (tis-
sue-specific-R26Met). (B, C) Whole mount (B) or transverse section (C) β-galactosidase staining
of E10.5 R26stopMet and Del-R26Met embryos. Note that different degree of Cre-mediated
recombination results in Del-R26Met mutants with high (right) or low (middle) β-galactosidase
activity. hb: hindbrain; ov: optic vesicles; sc: spinal cord; di: diencephalon. (D) Genotype analy-
sis of embryos showing the mutant allele before and after Cre recombination. Note that the
efficiency of Cre-mediated recombination results into Del-R26Met embryos with total (right) or
partial (middle) deletion of the LacZ-stop cassette. Scale: 500μm.
(TIF)
S2 Fig. Expression pattern of humanMet and mouseMet in control and Del-R26Met
embryos.Whole mount ISH with humanMet (hMet) and mouse Met (mMet) probes in E10.5
control and Del-R26Met embryos. Scale: 500μm.
(TIF)
S3 Fig. Immunohistochemical analysis of phospho-Met and transgenic Met in E16.5 con-
trol and Del-R26Met embryos. (A) In Del-R26Met embryos, whereas Mettg (detected by human
Met antibodies; hMet) is expressed by most cell types in all tissues, phospho-Met is present
only in a restricted number of cell types. Middle and bottom panels show enlargement of top
panels at the levels of different organs. (B) Schematic representation of E16.5 embryos showing
the level of sections reported in panel A and C. (C) Immunohistochemical analysis of phos-
pho-Met and human Met (hMet) in control embryos showing background levels. (D)
Table summarizing organs positive or not for phospho-Met. Scale: 200μm.
(TIF)
S4 Fig. Genetic analysis of muscle development using theMLC-LacZ transgenics. (A)
Whole mount β-galactosidase staining showing reduced developing appendicular muscles in
E13.5 Del-R26Met embryos compared to controls. Note residual cytoplasmic β-galactosidase
staining in the R26stopMet line due to a small proportion of cells in which the LacZ-stop cassette
was not completely deleted. (B) Schematic representation of transgenic mice carrying the
MLC-LacZ transgene alone (controls) or together with the transgenic Met in Del-R26Met
embryos (limbs are outlined in bottom panels). Scale: 500μm.
(TIF)
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S5 Fig. Genetic analysis of migrating myoblasts in Prx1-R26Met and Pax3-R26Met condi-
tional mutants. (A, B) Whole mount ISH of embryos with Pax3 probe showing reduced
migrating myoblasts in the forelimbs of Prx1-R26Met (A), but not of Pax3-R26Met (B) embryos.
As in Pax3-Cre line the Cre gene is inserted in the Pax3 locus resulting also into a loss-of-func-
tional allele, the adequate control embryos in panel B correspond to Pax3-Cre heterozygous
(Pax3). (C, D) Quantification analyses of Pax3 positive domain in forelimbs. Left panels: each
plot represents the average signal distribution along the white line in forelimbs. Right panels:
quantifications and statistical analyses of the sum of signal intensity based on intensity plots in
left panels. Numbers of samples: control, n = 11; Prx1-R26Met, n = 6; Pax3, n = 4; Pax3-R26Met,
n = 4. The sum of Pax3 signal intensity was calculated between point A and B: A indicating a
fixed position between the somites and the limb whereas B being placed at a fixed distance
from A. Note the reduced Pax3 level in Prx1-R26Met mutants. (E) Left panels: Whole mount
ISH of E12.5 embryos withMyoD probe showing reduced developing appendicular muscles in
Prx1-R26Met mutants (limbs are outlined in bottom panels). Right panel: Prx1-R26Met mice at
birth show hyperflexed forelimbs. Scale: 500μm.
(TIF)
S6 Fig. Ectopic Met in developing limbs does not cause major patterning defects. (A)
Whole mount ISH of E10.5 control and Del-R26Met embryos with Shh (top) and Fgf8 (bottom)
probes. Note that Shh and Fgf8 expression remain located in the posterior limb bud mesen-
chyme and in the apical ectodermal ridge, respectively. Scale: 500μm. (B) Skeletal staining of
P0 control and Del-R26Met limbs showing no major patterning defects. Note that the deltoid
tuberosity in the humerus is significantly reduced in Del-R26Met mutants (100%: n = 7). As the
deltoid tuberosity requires muscle mechanical forces at later stages besides initiating signals
such as BMP4 [65], it is likely that this defect is a consequence of lack of muscles rather than a
phenotype caused by ectopic Met in limb mesenchyme. Scale: 2mm.
(TIF)
S7 Fig. qRT-PCR analyses on the expression levels of candidate genes in control andDel-
R26Met embryos. (A) qRT-PCR analysis of human Met (hMet) and LacZ transcripts in E10.5
control (n = 11) and Del-R26Met (n = 11) limbs. Each dots corresponds to transcript levels in
forelimbs of E10.5 individual embryos (done in triplicate). Columns correspond to the average
value, expressed as mean. Note that upregulation ofMettg (hMet) is paralleled by downregula-
tion of the LacZ transcripts in Del-R26Met embryos. (B, C) qRT-PCR analysis of candidate
genes in E10.5 control and Del-R26Met mutant limbs. No significant changes are observed.
Hs2st1: heparan sulphate 2-O sulfotransferase 1.Hs3st1: heparan sulphate 3-O sulfotransferase
1. Sdf1: stromal cell-derived factor 1. Columns correspond to the average value, expressed as
mean ± s.e.m. Mann-Whitney and Student-t test.
(TIF)
S8 Fig. Met expression as visualized by the knock-in of the lacZ reporter in theMet locus.
(A, B) Whole mount β-galactosidase staining showingMet distribution in developing muscles
of E10.5 (A) and E13.5 (B)MetLacZ/+ andMetLacZ/d(neo) embryos. Note: a) the absence of mus-
cles in limbs of E10.5 and E13.5MetLacZ/d(neo) embryos; b) thatMet expression is restricted to a
subgroups of developing muscles at E13.5; c) that developing limb tendons express alsoMet at
E13.5 and the pattern of expression is not altered inMetLacZ/d(neo) mutants. Scale: 500μm.
(TIF)
S9 Fig. Ectopic Met in limb mesenchyme does not affect HGF levels in conditioned media
from limb mesenchymal cells, but alters HGF bioavailability. (A) Western blot analysis of
conditioned media from control and Del-R26Met limb mesenchymal cells after enrichment with
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heparin (left) or lectin (right) beads. Note no major differences in the level of uncleaved HGF
between control and mutants. Numbers on the top of control and mutant lanes correspond to
quantification analyses of uncleaved HGF. Quantification of the processed form of HGF was
not performed because of the presence of a nonspecific band with the same molecular weight
(ns). Lanes with human recombinant HGF (rec-hHGF: 5ng) and non-conditioned media
(media) after purification. (B) Quantitative analysis of MDCK cell scattering using co-cultures
with dissected forelimbs from control and Del-R26Met embryos with a recombination efficiency
higher or lower than 60%. Quantification was performed according to categories defined in Fig
9B. Note a significant increase of cell colonies corresponding to the 1st category using forelimbs
from highly recombined Del-R26Met mutants (control: n = 14; Del-R26Met>60% recombina-
tion: n = 5; Del-R26Met<60% recombination: n = 3). Mann-Whitney and Student-t test.
(TIF)
S1 Table. Primer sequences used for qRT-PCR analyses.
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